Drug Search Results
More Filters [+]

Pexiganan

Alternative Names: pexiganan, msi-78, msi78, msi 78
Latest Update: 2024-01-11
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Magainin-2 Analogue

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Abeona
Company Location: NEW YORK NY 10019
Company CEO: Vishwas Seshadri
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pexiganan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Communicable Diseases|Diabetic Foot

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OneStep-1

P3

Completed

Communicable Diseases|Diabetic Foot

2016-08-01

OneStep-2

P3

Completed

Diabetic Foot|Communicable Diseases

2016-07-01

MSI-78-304

P3

Completed

Diabetic Foot

1996-07-01

73%

MSI-78-303

P3

Completed

Diabetic Foot

1996-07-01

73%

Recent News Events